Type III apparatus of Pseudomonas aeruginosa as a tool to diagnose pulmonary infection in cystic fibrosis patients

APMIS

Volumn 120, Issue 8, 2012, Pages 622-627

  Cruz, Aline C ^a   Neves, Bianca C ^b   Higa, Laurinda Y S ^c   Folescu, Tânia ^c   Marques, Elizabeth A ^a   Milagres, Lucimar G ^a  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Antibody response; Cystic fibrosis; Diagnosis; P. aeruginosa; Pulmonary infection

Indexed keywords

BACTERIAL PROTEIN; IMMUNOGLOBULIN G ANTIBODY; TYPE III SECRETION SYSTEM PROTEIN EXOS; TYPE III SECRETION SYSTEM PROTEIN EXOT; TYPE III SECRETION SYSTEM PROTEIN POPB; TYPE III SECRETION SYSTEM PROTEIN POPD; UNCLASSIFIED DRUG;

ADOLESCENT; ANTIBODY RESPONSE; ARTICLE; BACTERIUM DETECTION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; HUMAN; HUMAN TISSUE; LUNG INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN SECRETION; PSEUDOMONAS AERUGINOSA; SCHOOL CHILD; SEROLOGY; TYPE III SECRETION SYSTEM; WESTERN BLOTTING;

ADOLESCENT; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; CYSTIC FIBROSIS; HUMANS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS; RETROSPECTIVE STUDIES;

EID: 84863817348     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2012.02888.x     Document Type: Article

References (13)

1. Döring G, Conway SP, Heijerman HG, Hodson ME, Høiby N, Smyth A, et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 2000;16:749-67.
2. Milagres LG, Castro TLA, Garcia D, Cruz AC, Higa L, Folescu T, et al. Antibody response to Pseudomonas aeruginosa in children with cystic fibrosis. Pediatr Pulmonol 2009;44:392-401.
3. West SE, Zeng L, Lee BL, Kosorok MR, Laxova A, Rock MJ, et al. Respiratory infections with Pseudomonas aeruginosa in children with cystic fibrosis: early detection by serology and assessment of risk factors. JAMA 2002;12:2958-67.
4. Corech R, Rao A, Laxova A, Moss J, Rock MJ, Li Z, et al. Early immune response to the components of the type III system of Pseudomonas aeruginosa in children with cystic fibrosis. J Clin Microbiol 2005;43:3956-62.
5. Jain M, Ramirez D, Seshadri R, Cullina JF, Powers CA, Schulert GS, et al. Type III secretion phenotypes of Pseudomonas aeruginosa strains change during infection of individuals with cystic fibrosis. J Clin Microbiol 2004;42:5229-37.
6. Blonder-Hill E, Henry DA, Speert DP. Pseudomonas. In: Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA, editors. Manual of Clinical Microbiology. Washington, DC, ASM Press, 2007.
7. Saliba AM, Filloux A, Ball G, Silva ASV, Assis MC, Plotkowski MC. Type III secretion-mediated killing of endothelial cells by Pseudomonas aeruginosa. Microb Pathog 2002;33:153-66.
8. Wedege E, Bolstad K, Wetzler LM, Guttormsen HK. IgG antibody level to meningococcal porins in patient sera: comparison of immunoblotting and ELISA measurements. J Immunol Methods 2000;24:9-15.
9. Li L, Ledizet M, Kar K, Koski RA, Kazmierczak BI. An indirect enzyme-linked immunosorbent assay for rapid and quantitative assessment of Type III virulence phenotypes of Pseudomonas aeruginosa isolates. Ann Clin Microbiol Antimicrob 2005;4:22-35.
10. Sawa T, Yahr TL, Ohara M, Kurahashi K, Gropper MA, Wiener-Kronish JP, et al. Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury. Nat Med 1999;5:392-8.
11. Goure J, Pastor A, Faudry E, Chabert J, Dessen A, Attree I. The V Antigen of Pseudomonas aeruginosa is required for assembly of the functional PopB/PopD translocation pore in host cell membranes. Infect Immun 2004;72:4741-50.
12. Farrel PM, Govan JRW. Pseudomonas serology: confusion, controversy, and challenge. Thorax 2006;61:645-7.
13. Pressler T, Frederiksen B, Skov M, Garred P, Koch C, Hoiby N. Early rise of anti-Pseudomonas antibodies and a mucoid phenotype of Pseudomonas aeruginosa are risk factors for development of chronic lung infection-a case control study. J Cyst Fibros 2006;5:9-15.